Clinical Trials

44 enrolled

Breast Neoplasms

NCT05768139 2026-05-22

PIKALO-1

BreastGynecologicHead & Neck

880 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07174336 2026-05-22

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07492641 2026-05-22

KANDELA-302

1,056 enrolled

HR+/HER2- Breast Cancer

NCT07340541 2026-05-20

EVOLVE-BDT

700 enrolled

Phase 3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06760637 2026-05-19

FourLight-3

1,035 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT07100106 2026-05-18

MoonROSE

285 enrolled

Breast Neoplasms

NCT06380751 2026-05-15

EvoPAR-BR01

500 enrolled

Advanced Breast Cancer

NCT05372640 2026-05-13

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Phase 1 Recruiting

45 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06188520 2026-05-11

CYCAD-1

564 enrolled

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06065748 2026-05-05

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

1,050 enrolled

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT04305834 2026-05-04

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

43 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT03616587 2026-04-30

SERENA-1

396 enrolled

Breast Neoplasms

NCT05501704 2026-04-30

ETHAN - ET for Male BC

60 enrolled

Breast Neoplasms, Male

NCT05608252 2026-04-30

VS-6766+Abema+Fulv in Met HR+/HER- BC

63 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT03939897 2026-04-29

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

24 enrolled 15 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT03155997 2026-04-24

monarchE

5,637 enrolled 12 charts 2 FDA

Phase 3 Active not recruiting

Breast Neoplasms

NCT04964934 2026-04-21

SERENA-6

315 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT05696626 2026-04-21

ELAINEIII

500 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT05307705 2026-04-20

PIKASSO-01

193 enrolled

Breast Neoplasms

NCT06179303 2026-04-16

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

60 enrolled

Phase 2 Active not recruiting

Anatomic Stage III Breast Cancer AJCC v8

NCT04920708 2026-04-14

FAIM

57 enrolled

Breast Neoplasms

NCT05095207 2026-04-13

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

42 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05386108 2026-04-06

ELECTRA